311 related articles for article (PubMed ID: 32106568)
1. Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with
Cędrowska E; Pruszyński M; Gawęda W; Żuk M; Krysiński P; Bruchertseifer F; Morgenstern A; Karageorgou MA; Bouziotis P; Bilewicz A
Molecules; 2020 Feb; 25(5):. PubMed ID: 32106568
[TBL] [Abstract][Full Text] [Related]
2. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy.
Gawęda W; Pruszyński M; Cędrowska E; Rodak M; Majkowska-Pilip A; Gaweł D; Bruchertseifer F; Morgenstern A; Bilewicz A
Nanomaterials (Basel); 2020 Oct; 10(10):. PubMed ID: 33092037
[TBL] [Abstract][Full Text] [Related]
4. Triple Therapy of HER2
Zolata H; Afarideh H; Davani FA
Cancer Biother Radiopharm; 2016 Nov; 31(9):324-329. PubMed ID: 27831759
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab-conjugated liposome-coated fluorescent magnetic nanoparticles to target breast cancer.
Jang M; Yoon YI; Kwon YS; Yoon TJ; Lee HJ; Hwang SI; Yun BL; Kim SM
Korean J Radiol; 2014; 15(4):411-22. PubMed ID: 25053899
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab-Modified Gold Nanoparticles Labeled with
Dziawer Ł; Majkowska-Pilip A; Gaweł D; Godlewska M; Pruszyński M; Jastrzębski J; Wąs B; Bilewicz A
Nanomaterials (Basel); 2019 Apr; 9(4):. PubMed ID: 31003512
[TBL] [Abstract][Full Text] [Related]
8. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
9. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
10. Targeted actinium-225 in vivo generators for therapy of ovarian cancer.
Borchardt PE; Yuan RR; Miederer M; McDevitt MR; Scheinberg DA
Cancer Res; 2003 Aug; 63(16):5084-90. PubMed ID: 12941838
[TBL] [Abstract][Full Text] [Related]
11. Hybrid Radiobioconjugated Superparamagnetic Iron Oxide-Based Nanoparticles for Multimodal Cancer Therapy.
Żuk M; Gawęda W; Majkowska-Pilip A; Osial M; Wolski M; Bilewicz A; Krysiński P
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834258
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional Nanoparticles Based on Iron Oxide and Gold-198 Designed for Magnetic Hyperthermia and Radionuclide Therapy as a Potential Tool for Combined HER2-Positive Cancer Treatment.
Żuk M; Podgórski R; Ruszczyńska A; Ciach T; Majkowska-Pilip A; Bilewicz A; Krysiński P
Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015306
[TBL] [Abstract][Full Text] [Related]
13. Effects of multiple injections on the efficacy and cytotoxicity of folate-targeted magnetite nanoparticles as theranostic agents for MRI detection and magnetic hyperthermia therapy of tumor cells.
Soleymani M; Khalighfard S; Khodayari S; Khodayari H; Kalhori MR; Hadjighassem MR; Shaterabadi Z; Alizadeh AM
Sci Rep; 2020 Feb; 10(1):1695. PubMed ID: 32015364
[TBL] [Abstract][Full Text] [Related]
14. Selection of potential iron oxide nanoparticles for breast cancer treatment based on in vitro cytotoxicity and cellular uptake.
Poller JM; Zaloga J; Schreiber E; Unterweger H; Janko C; Radon P; Eberbeck D; Trahms L; Alexiou C; Friedrich RP
Int J Nanomedicine; 2017; 12():3207-3220. PubMed ID: 28458541
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization and in vitro evaluation of exquisite targeting SPIONs-PEG-HER in HER2+ human breast cancer cells.
Almaki JH; Nasiri R; Idris A; Majid FA; Salouti M; Wong TS; Dabagh S; Marvibaigi M; Amini N
Nanotechnology; 2016 Mar; 27(10):105601. PubMed ID: 26861770
[TBL] [Abstract][Full Text] [Related]
16. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of breast cancer cells to radiation by trastuzumab.
Liang K; Lu Y; Jin W; Ang KK; Milas L; Fan Z
Mol Cancer Ther; 2003 Nov; 2(11):1113-20. PubMed ID: 14617784
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional superparamagnetic nanoparticles conjugated with fluorescein-labeled designed ankyrin repeat protein as an efficient HER2-targeted probe in breast cancer.
Li DL; Tan JE; Tian Y; Huang S; Sun PH; Wang M; Han YJ; Li HS; Wu HB; Zhang XM; Xu YK; Wang QS
Biomaterials; 2017 Dec; 147():86-98. PubMed ID: 28938164
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728.
Irie H; Kawabata R; Fujioka Y; Nakagawa F; Itadani H; Nagase H; Ito K; Uchida J; Ohkubo S; Matsuo K
Cancer Sci; 2020 Jun; 111(6):2123-2131. PubMed ID: 32248641
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic evaluation of magnetic hyperthermia using Fe3O4-aminosilane-coated iron oxide nanoparticles in glioblastoma animal model.
Rego GNA; Mamani JB; Souza TKF; Nucci MP; Silva HRD; Gamarra LF
Einstein (Sao Paulo); 2019 Aug; 17(4):eAO4786. PubMed ID: 31390427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
